Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Registration Number
- NCT04699968
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04694365
- Locations
- 🇨🇳
Henan Infectious Diseases Hospital, Zhengzhou, Henan, China
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 486
- Registration Number
- NCT04691063
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 804
- Registration Number
- NCT04691804
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Center for Onology and Blood Disorders, Houston, Texas, United States
🇨🇳Affiliated Hospital of Guizhou Medical University, Guiyang, China
Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04688008
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT04680988
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04680091
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT04679038
- Locations
- 🇨🇳
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04676035
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 760
- Registration Number
- NCT04667143
© Copyright 2024. All Rights Reserved by MedPath